516 articles in this topic
A new AI model spots pancreatic cancer on standard CT scans nearly 16 months before radiologists can see it — with nearly 3x their sensitivity.
A 73-patient study finds PD-L1 expression and TERT mutations identify high-grade thyroid cancers most likely to benefit from checkpoint inhibitor therapy.
Zongertinib and sevabertinib earn FDA accelerated approvals for HER2-mutant NSCLC, expanding targeted therapy options for a historically hard-to-treat subset.
Researchers respond to peer critique of risk-based, non-invasive hepatocellular carcinoma surveillance in metabolic liver disease patients.
Retrospective study of 120 NSCLC patients finds thymalfasin plus chemoimmunotherapy significantly extends PFS and OS without added toxicity.
A next-gen RAS inhibitor called daraxonrasib targets KRAS-mutant cholangiocarcinoma, showing strong preclinical results and early clinical activity.
JYP0322 overcomes drug resistance and penetrates the brain, showing remarkable efficacy in heavily pretreated NSCLC patients.
A growth factor called GDF11 reprograms pro-tumor macrophages by rewiring their metabolism, suppressing hepatocellular carcinoma growth.
New 3-D spatial mapping reveals four distinct immune-evasion niches in osteosarcoma that explain why checkpoint therapies fail.
A large pooled study finds heavy drinking raises colorectal cancer risk across all molecular subtypes, suggesting a broad carcinogenic mechanism.
A blood-based immune biomarker predicts which breast cancer patients will respond to checkpoint immunotherapy, validated across two independent cohorts.
Researchers clarify how a clinical-radiological model can guide—and where it falls short—in managing hepatocellular carcinoma treated with TACE.
